Form 4: Serina Therapeutics CSO Sells Shares Under 10b5-1 Plan

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, sold 6,500 shares of common stock after exercising options, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• Randall Moreadith, Chief Scientific Officer of Serina Therapeutics, Inc., executed transactions involving the exercise of stock options and subsequent sale of common stock.
• On January 13, 2026, Mr. Moreadith exercised options to acquire 5,416 shares of common stock at an exercise price of $0.06 per share.
• Immediately following the exercise on January 13, 2026, he sold all 5,416 shares at a price of $2.50 per share.
• On January 14, 2026, Mr. Moreadith exercised options to acquire an additional 1,084 shares of common stock at an exercise price of $0.06 per share.
• Immediately following the exercise on January 14, 2026, he sold all 1,084 shares at a weighted average price of $2.5031 per share, with individual sales ranging from $2.50 to $2.54.
• All transactions were conducted under a Rule 10b5-1(c) contract, instruction, or written plan.
• Following these transactions, Mr. Moreadith beneficially owns 0 shares of common stock directly from these specific transactions, but still holds 332,686 vested stock options.

Sentiment

Score: 5

Explanation: The sale of shares by a Chief Scientific Officer could be perceived negatively, but the execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling based on undisclosed information, making it a neutral event.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating a pre-scheduled sale rather than a reaction to new, non-public information.
• The officer exercised fully vested stock options, realizing a gain.

Negatives

• An officer of the company sold a total of 6,500 shares of common stock.

Future Outlook

NA

Industry Context

This filing details a routine insider transaction by a Chief Scientific Officer, common in the biotechnology and pharmaceutical sectors where executive compensation often includes stock options. The use of a 10b5-1 plan is a standard practice for insiders to manage their equity holdings while complying with insider trading regulations.

Related Party Transactions

• Randall Moreadith, Chief Scientific Officer, exercised stock options and sold common stock of Serina Therapeutics, Inc.

Stakeholder Impact

• Shareholders: May observe a slight negative sentiment due to insider selling, though mitigated by the 10b5-1 plan.
• Employees: No direct impact indicated.
• Customers: No direct impact indicated.
• Suppliers: No direct impact indicated.
• Creditors: No direct impact indicated.

Key Dates

Recommendation

The filing reports a routine insider transaction by the Chief Scientific Officer, Randall Moreadith, involving the exercise of vested stock options and subsequent sale of shares under a pre-arranged 10b5-1 plan. This type of transaction is common for executive compensation and, given the 10b5-1 plan, does not typically signal a change in the company's fundamental outlook or management's confidence. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Serina Therapeutics, SER, Randall Moreadith, Chief Scientific Officer, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Equity Transaction